Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test by unknown
 




Chylomicron remnant metabolism in familial







































 The University of Western Australia, Nedlands, Perth, Australia 




 Royal Perth Hospital, Box X2213, Perth, Australia 6847; 




 the University of Cape Town, Health Science Faculty, Observatory,
7925 South Africa
 
Abstract We have developed a stable isotope breath test for
the assessment of chylomicron remnant metabolism and report
the results from the breath test in human subjects selected for
disorders of chylomicron or remnant metabolism. In type I hy-
perlipemia, the phenotype is extreme hypertriglyceridemia due
to a lack of lipoprotein lipase activity, which causes the failure
of remnant formation. The type III dyslipidemia phenotype is
caused by the inefficient removal of chylomicron remnants
from plasma, generally because of homozygosity for apolipo-
protein E2 alleles. The breath test was predicted to be abnor-
mal in type III hyperlipemia, whereas a priori in type I hyper-
lipemia defective remnant clearance was not anticipated.
Subjects were injected with lipid emulsions prepared with a
composition similar to normal chylomicron remnants. The





C in the fatty acid moiety. End exhala-
tion breath was collected at intervals after intravenous injec-





ment by isotope-ratio mass spectrometry. Compared with the
group of normolipemic men, the fractional catabolic rate of







 0.006) in subjects with type III dyslipidemia. In
the group with type I hyperlipemia, the fractional catabolic rate






 0.233) from the control group. There-
fore, the underlying capacity for remnant catabolism was nor-
mal in this group of markedly hypertriglyceridemic subjects.
By short-circuiting the step of lipolysis, the remnant-like emul-
sion breath test provides direct information about remnant
clearance and metabolism, which should assist in investigations
of postprandial lipid metabolism.
 
—Redgrave, T. G., G. F.
Watts, I. J. Martins, P. H. R. Barrett, J. C. L. Mamo, S. B. Dim-
mitt, and A. D. Marais. 
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There is increasing need for assessment of the capacity
of individual subjects to metabolize the remnants of triglyc-
eride-rich lipoproteins because of growing awareness of
the contribution of remnants to atherogenesis (1). Exist-
 
ing methods rely on the measurement of apoB-48 in
plasma or on the postprandial changes in ingested vita-
min A, but neither of these methods clearly distinguishes
between defective lipolysis and problems of remnant
clearance. We report here the results in selected groups of
subjects of an investigation of remnant metabolism using
a remnant-like emulsion breath test. The new breath test
overcomes difficulties in measuring remnant metabolism
in humans and is timely because the cholesterol-enriched
remnants of triglyceride-rich lipoproteins play a role in ac-
celerated atherosclerosis (2–4).
The triglyceride-rich chylomicrons secreted by the in-
testine and very low density lipoprotein (VLDL) secreted
by the liver are substrates for lipoprotein lipase, which hy-
drolyzes a proportion of the particle triglyceride content
to produce a remnant particle that is smaller in size, con-
tains fewer triglycerides and phospholipids, and is rela-
tively enriched in its content of free and ester cholesterol
(5). The remnants are then removed by receptor-mediated
endocytosis, normally predominantly by the liver, with small
uptakes by other tissues, including arteries (6). Plasma apo-
lipoproteins are essential for the catabolism of remnants,
particularly apoCII as a cofactor for lipase action and apoE
as a ligand for the removal of remnants from plasma by re-
ceptors expressed in the liver and other tissues (7).
Direct measurements of remnant metabolism in hu-
mans are difficult to make because nascent triglyceride-
rich lipoproteins cannot be collected for study. Some stud-
ies have been done with plasma fractions enriched with
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remnants, but this approach is not suited for routine ap-
plications (8). An alternative strategy is to employ artificial
lipoproteins that are formulated to mimic the composi-
tion and physiology of normal triglyceride-rich lipopro-
teins. This approach was first applied using lipid emulsion
models of lymph chylomicrons (9) and has since provided
important insights into chylomicron metabolism in hu-
mans (10–16).
More recently, lipid emulsion models of remnant parti-
cles have been developed (17), and these are employed in
the new breath test. The remnant-like emulsions do not
require lipolysis before associating with apoE, which then
mediates uptake by the liver. The emulsions incorporate




C to label the fatty
acid moiety of cholesteryl esters in the remnant-like parti-
cles. After injection, the lipid emulsions rapidly gain apoE
from plasma and are endocytosed by the liver. In the liver,
hydrolysis of the remnant cholesteryl esters in lysosomes





, providing a simple measure of catabolism of the









 can be directly quantitated by isotope-






Subjects with proven types I and III hyperlipemia were studied
following an intravenous injection of a remnant-like emulsion.





15 mmol/l were demonstrated to have
chylomicron accumulation as well as absent post-heparin lipase
activity. There were five male and four female subjects with an
average age of 27 years (range 12 –48 years). Type III hyper-
lipemia was diagnosed by ultracentrifugation of plasma lipopro-
teins to confirm the presence of a cholesterol-rich VLDL frac-
tion and by genotyping apoE to confirm the presence of
homozygosity for the apoE2 allele, or in two subjects the pres-
ence of one of the rare dominant mutations of apoE. There were
13 male and 4 female subjects with an average age of 53 years
(range 44–65 years). All patients were receiving fat-modified diets
for their hyperlipemia and were in stable body weight. A control
group of subjects was recruited with an average age of 44 years









1.8 mmol/l. None of the control subjects had a
history of cardiovascular disease. One of the control subjects but
none of the type I subjects was homozygous for apoE2. General









diabetes, proteinuria, thyroid disease, lipid-regulating therapy,
or acute illness. The studies received approval from the Ethics
Review Committees of Royal Perth Hospital and the University








C]oleic acid was purchased from Nova-









C]oleic acid as described previ-





C]oleic acid and cholesterol were reacted for 17 h at room tem-
perature in dry carbon tetrachloride with 107 mol% of dicyclohex-
ylcarbodiimide in the presence of 16 mol% N,N-dimethylami-
nopyridine. A 1% volume of water was added, and after stirring for
4 h, the mixture was extracted with petroleum spirits and then 2%
diethyl ether in petroleum. After filtration through a small silica
column, fractions shown by thin-layer chromatography to contain
cholesteryl ester were combined, reduced in volume, and purified
by flash chromatography on silica gel. After drying under high





























). Structure was confirmed by proton
nuclear magnetic resonance (details available on request).
Lipid mixtures containing triolein (135 mg), phosphatidyl-




C]oleate (70 mg), and choles-
terol (24 mg) (all more than 99% pure) were emulsified by soni-
cation for 1 h in 8.5 ml of 2.2% glycerol in water. After
sonication, the emulsion mixture was centrifuged at 3,000 rpm





m filter into sterile vessels. Emulsion prepara-





14 ml) was placed into a sterile syringe and













warmed to room temperature just before use. The remnant-like








40)] measured by negative-stain electron microscopy. The com-
























Breath test clinical procedure
 
Two baseline (zero-time) breath samples were collected from
subjects who had fasted for 14 h overnight. Subjects were in-
jected intravenously with the remnant-like emulsion. Breath
samples were obtained by having the subjects exhale fully
through a drinking straw and into a tube. Alveolar air was sam-
pled, and the tube was immediately capped. Breath samples
were obtained at intervals over 24 h (10, 20, 30, 40, and 50 min
and then 1, 2, 3, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 11, 12, 21, and
24 h after injection). Subjects sat quietly during the first 8 to 9 h
of the study, after which they consumed a light meal and re-





 in the exhaled breath samples was analyzed by isotope-ratio
mass spectroscopy using a Finnigan BreathmatPlus machine
















 was referenced to Peedeebelimnite standard val-
ues, and the delta unit value was calculated using the Breathmat
software. The delta units reference a sample of limestone, a stan-




C isotope ratio field, and basal (non-enriched) val-




C, with small variations
depending on the proportions of diet deriving from C3 or C4
photosynthesis (see Discussion).
 
Plasma lipid and apolipoprotein analysis
 
Plasma lipids were measured by automated hospital routines
according to standard procedures. ApoB-48 was quantitated as
previously described (18). Briefly, chylomicrons and their rem-
nants were isolated from plasma by ultracentrifugation. ApoB-48
was separated from other proteins by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and transferred to membranes that
were incubated with a rabbit antibody to apoB, then reacted with
anti-rabbit IgG (horseradish peroxide conjugated) and enhanced
chemiluminescence reagent (Amersham). After development,
the apoB-48 bands were quantified by densitometry and stan-
dardized against purified apoB-48 protein of known mass. The
inter- and intra-assay variabilities were 9% and 5%, respectively.
 




Mathematical modeling of breath enrichment data
 





 in breath was developed using the SAAM II program
(SAAM Institute, Seattle, WA). The model was developed assum-
ing that the fractional rate constants [k(i,j)] were time invariant





Compartment 1 of the model represents the plasma compart-
ment into which the labeled remnant-like emulsion is injected.
Material in compartment 1 can be lost from plasma to compart-





and is sampled during the course of the study. The primary path-





 is via compartment 3. This compartment may include the
processes associated with uptake and hydrolysis of the labeled








 breath data, and estimates of the fractional catabolic rate
(FCR) were determined as the sum of the two rate constants out









All analyses were carried out using the Statistical Packages for


















Plasma lipids, lipoproteins, and apoB-48
 
Plasma triglycerides, total cholesterol, high-density lipo-
protein (HDL) cholesterol, and apoB-48 measurements




. Compared with the group of
normolipemic men, the group with type I hyperlipemia

















0.001), whereas total plasma cholesterol was not signifi-
cantly different, although the variance was larger in this
group. In the group with type III hyperlipemia, plasma









 0.001), whereas plasma HDL cho-

































C in the breath of the normolipemic, type I hy-
perlipemic, and type III hyperlipemic subjects. Fig. 2A
shows that, in the normolipemic controls subjects, the en-
richment increased rapidly by an average of more than 6
units to reach a peak approximately 5 h after injection of
the emulsion, followed by a progressive slow decline ex-
cept for a discontinuity at about 10 h toward pre-injection
values over the ensuing 18 h. Fig. 2B shows that the initial
starting enrichment value was approximately 2 units higher




). Nevertheless, in the group
with type I hyperlipemia there was significant enrichment,
rising to a peak approximately 4 units above baseline about
5 h after injection of the emulsion. Fig. 2C shows that the
responses of the group with type III hyperlipemia were re-





less than 2 units from baseline over the course of the study.
The rate constants of the model used to derive the frac-
tional clearance rates are shown in Table 2. Only k(3,1)









 0.005), and this rate constant is
the principal determinant of the FCR of the remnant-like
emulsion (see Methods). The FCR of the injected rem-





. Compared with the group of normolipemic
men, the group with type I hyperlipemia showed a small
decrease in FCR, but the difference was not significant, as
shown by the considerable overlap in confidence intervals
with the control group. In contrast, the group with type
III hyperlipemia showed a significant decrease in FCR,
with no overlaps in confidence intervals compared with









Fig. 1. Representation of the compartmental model used to fit
the breath test enrichment data. The plasma compartment into
which the 13C-labeled material is injected is compartment 1. Com-
partment 2 represents the breath, which is sampled during the
course of the study, and compartment 3 represents the main path-
ways for clearance and metabolism of the injected label within the
body before the appearance of 13CO2 in the breath.
 
TABLE 1. Plasma lipid, lipoproteins, and apolipoprotein B-48 (apoB-48) contents in the control subjects
and in patients with familial hyperlipemia
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DISCUSSION
We recently developed remnant-like emulsions, which,
when injected into mice, became associated with apoE
and were rapidly taken up by the liver. Incorporated
[13C]cholesteryl oleate was metabolized and appeared as
13CO2 in expired breath (19, 20). In the present study,
remnant catabolism using the breath test was measured in
groups of subjects with familial hyperlipemia. The breath
test was severely impaired in subjects with type III dyslipi-
demia, which we expected because of the known associa-
tion with defective remnant clearance in the type III phe-
notype (4). Cardiovascular disease risk is increased in type
III dyslipidemia, consistent with the involvement of abnor-
mal remnant clearance.
The initial starting enrichment value was approximately
2 units higher in the type I subjects, probably reflecting
the very low fat diets consumed by this group. Endoge-
nous 13C enrichment varies between food groups (21, 22)
and therefore is affected by dietary sources. The disconti-
nuity at about 10 h seen in all groups of subjects corre-
sponds to the resumption of normal daily activities and
the consumption of a light meal. The breath test depends
not only on plasma removal of the emulsion remnant par-
ticles into the liver for catabolism but also on the subse-
quent metabolism of fatty acids hydrolyzed from the emul-
sion cholesteryl ester. Changes in fluxes of fatty acids in
the liver could therefore possibly confound the interpreta-
tion of the enrichment data. Fatty acid kinetics have been
found to be different from controls in patients with famil-
ial combined hyperlipidemia (23, 24) in association with
impaired postprandial lipid metabolism. We are unaware
of parallel findings in subjects with type I or type III dyslip-
idemia. Whereas the findings of the present study are
clearly consistent with the present interpretation, it is still
possible that changes in fatty acid flux contributed to the
result. Nevertheless, the findings are consistent with other
evidence that remnant clearance is abnormal in type III
hyperlipemia, whereas a priori there is no reason to antic-
ipate abnormal remnant clearance in type I hyperlipemia.
An uncertainty with the interpretation of the breath test
data is the potential influence of the pool size and flux
rate of the fatty acid oxidation pathway. For example, if a
patient were depleted in hepatic glycogen and the
insulin -glucagon ratio was low, more of the 13C fatty acid
would be expected to be oxidized instead of re-esterified.
Further direct experimentation is needed to determine
whether this phenomenon could influence the breath test
after an overnight fast, but preliminary findings in a series
of normolipidemic patients tested in our laboratory either
fasting or after a standard meal do not show any difference.
Another currently unresolved issue is the potential con-
founding influence of cholesteryl ester transfer protein
(CETP). It cannot be excluded that the emulsion choles-
teryl ester was transferred to other plasma lipoproteins be-
fore catabolism. There is no evidence that differences in
CETP activity are associated with type I or type III hyper-
lipemia, yet the expansion of pool size in acceptor lipo-
proteins possibly enhanced transfer. An argument against
this possibility is that the breath test was not different
from controls in the type I subjects. What are lacking are
deterministic studies of postprandial lipid metabolism in
individuals selected for high or low CETP activity. Inhibi-
tors of CETP have recently become available (25), and
their use may help to resolve this issue.
Whether plasma triglyceride concentrations predict car-
diovascular disease has been a contentious issue, perhaps
because the remnants of the triglyceride-rich lipoproteins
Fig. 2. The patterns of enrichment of the breath CO2 with 13C in
the control normolipemic subjects (A), in hypertriglyceridemic
subjects with type I hyperlipemia (B), and in subjects with hyper-
triglyceridemia and hypercholesterolemia due to type III hyper-
lipemia (C). The data are means with standard error bars, and the
line is that fitted by the compartmental model to the averaged data.
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are pro-atherogenic, whereas the primary particles, such
as chylomicrons, are not (26, 27). Whereas hypertriglycer-
idemia is generally associated with the increased risk of
cardiovascular disease, this is not true for subjects with
type I hyperlipemia where undegraded chylomicrons per-
sist in the circulation but the risk of cardiovascular disease
is not increased. In the present study, the subjects with
type I hyperlipemia were extremely hypertriglyceridemic.
However, the breath test was not different from normo-
lipemic control subjects. Therefore, despite the lack of
lipoprotein lipase activity, the underlying capacity for rem-
nant catabolism was normal in this group of subjects with
severe hypertriglyceridemia.
Measurements of the concentrations of remnants in
plasma are possible but are technically difficult because of
the low concentrations in plasma of remnants compared
with other lipoproteins (28, 29). In the past, postprandial
studies using vitamin A have led to useful insights relating
defective remnant clearance to increased atherosclerosis,
but the procedures are cumbersome, not practical for
routine screening, and perhaps unreliable (30). Other po-
tential markers for abnormal remnant metabolism are in-
creased plasma contents of apoB-48 and the remnant-like
particle cholesterol (RLP-C) test (28, 29, 31, 32). How-
ever, both the RLP-C test and measurements of apoB-48
lack specificity for distinguishing defects in lipolysis from
defects in remnant clearance, shown clearly by the
present study, where apoB-48 was increased in both type I
and type III hyperlipemic subjects (Table 1), whereas the
breath test was abnormal only in type III subjects (Table
2). Furthermore, for a rapid catabolic-pathway -like rem-
nant clearance and metabolism, a functional test, such as
the breath test, is desirable. The new breath test is simple
to administer, and clinical studies are now in progress to
determine its value in measuring the effects of therapeutic
interventions.
Analysis of the breath enrichment data by compartmen-
tal modeling is an important aspect of the method. One
of the advantages of the modeling is that the need for cor-
rection of emulsion dose for body size is obviated because
the fractional clearance rate is independent of individual
variation in this regard. The only restriction in metabolic
terms is that the subjects must not undertake physical ac-
tivity during the test, to prevent artifactual dilution of
label due to accelerated oxidation of unlabeled substrate.
The specificity of the breath test for detecting defective
remnant clearance in type III dyslipidemia testifies that
the breath test may be used to distinguish hypertriglyceri-
demic individuals at increased risk of cardiovascular dis-
ease from other individuals where a lipolysis defect may
cause hypertriglyceridemia without increased risk of car-
diovascular disease. This may be particularly relevant to
the one third of patients with coronary disease who have
increased triglyceride and normal cholesterol levels (33).
Additional studies with the breath test as the endpoint are
ongoing, testing the ability of various interventions to en-
hance remnant catabolism. Studies in progress using the
breath test include the effects of abdominal obesity and
type II diabetes on postprandial lipid metabolism. The
breath test can be carried out repeatedly in intervention
trials, for example to assess the impact on remnant clear-
ance of up-regulation of clearance pathways with lipid-
lowering drugs. The breath test has also been useful in
many studies of mice, testing the effects of a number of
obesity models and also of gene knockout and transgenic
manipulations (20).
The future usefulness of the breath test in clinical inves-
tigation will depend on whether it identifies individuals at
increased risk of cardiovascular diseases in the absence of
other conventional risk factors and whether it allows the
assessment of therapeutic interventions that decrease car-
diovascular risk. The breath test may prove easier to ad-
minister and interpret than presently available chromato-
graphic methods of measuring clearance of postprandial
lipids, particularly as stable isotope measurements be-
come more routine.
The clinical application of the breath test was supported by the
University of Western Australia and by a grant from the Lot-
teries Commission of Western Australia. Therapeutic interven-
TABLE  2. Basal 13C enrichments and model rate constants in the control subjects






Type III Hyperlipemic 
(n 	 17)
Basal enrichment (delta units) 24.7  0.28 22.9  0.42a 24.1  0.29
k(2,1) (h1) 0.024  0.006 0.022  0.007 0.008  0.005
k(3,1) (h1) 0.139  0.023 0.089  0.030 0.030  0.020b
k(2,3) (h1) 7.308  1.748 8.435  2.331 6.277  1.696
k(0,2) (h1) 1.363  0.263 1.416  0.351 0.977  0.255
Results are means  SEM. Significant differences from other groups by analysis of variance with Bonferroni
comparisons of means are indicated (a P  0.04 and b P  0.005).
TABLE 3. Fractional catabolic rate of chylomicron remnant-like 
emulsion calculated from 13C breath data in the control subjects






Normolipemic 16 3.91 0.93 1.93–5.96
Type I hyperlipemic 9 2.67 0.38 1.79–3.55
Type III hyperlipemic 17 0.91a 0.20 0.48–1.34
a Significant difference from normolipemic control subjects; P 
0.005.
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tion trials using the breath test have been supported by grants
from Merck Sharpe & Dohme and Bristol Myers Squibb. The
assistance of the research nurses and laboratory staff in Perth
and Cape Town is particularly acknowledged.
Manuscript received 12 June 2000, in revised form 14 November 2000, and in
re-revised form 21 December 2000.
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